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Objective:
Rituximab (RTX) is an anti-CD20 antibody used 
successfully in Granulomatosis with Polyangiitis (GPA) 
for induction and maintenance of remission. Our study 
aims to evaluate the long term efficacy and safety of 
chronic pre-emptive RTX therapy in GPA.
Results:
Conclusion:
Long term pre-emptive RTX maintenance is efficacious in 
reducing the risk for relapse but was discontinued in a third of
the patients.
Kidney involvement and the total CYC cumulative dose are 
important risk factors for severe infections.
The patients’ net state of immunodeficiency under RTX 
changes over time as low level of total immunoglobulins 
increases the risk for infections.
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Methods:
Retrospective study of 35 GPA patients treated with RTX 
between April 2004 and September 2011 for active disease and 
maintenance. RTX was initiated as two 1-gram infusions 2 weeks 
apart and thereafter 2gr RTX was re-administered annually. 
Patients were followed for 47 (2-88) months. They received a 
median RTX dose of 8g (2-13) dealt in 5 (1-10) rounds.
Risk factors for severe infections determined by univariate and multivariate (backward 
stepwise) binary logisitic regression analysis. All predictor variables in the analysis are 
continuous.
Risk factors for chronic infections determined by univariate and multivariate (backward 
stepwise) binary logistic regression. All predictors variables in this analysis are 
continuous.
Severe infections
(necessitating hospitalization and IV antibiotics)
Chronic infections
(symptomatic localized infections lasting >3 months and 
requiring several antibiotics courses)
Lower B cells at RTX initiation in patients with chronic 
infections compared with patients without chronic 
infections (Mann-Whitney U test: 0.035 vs. 0.09x10^9/L, 
p=0.065)
30.9 relapses /100 patient-years 
before RTX
